Completed PHASE4 INTERVENTIONAL 3-arm NCT04710134

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy

Sponsor: McMaster University

Conditions Asthma; Eosinophilic

Interventions Reslizumab

Updated 7 times since 2021 Last updated: Jan 24, 2024 Started: Feb 10, 2021 Primary completion: Jan 9, 2024 Completion: Jan 9, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04710134, this PHASE4 trial focuses on Asthma; Eosinophilic and remains completed. Sponsored by McMaster University, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Feb 2024 — Jul 2024 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Feb 2023 — Feb 2024 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Apr 2022 — Feb 2023 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Mar 2021 — Apr 2022 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Feb 2021 — Mar 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

McMaster University
Teva Canada

Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, Canada